- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$494.46

Market cap

$127.6B

P/E Ratio

31.74

Dividend/share

N/A

EPS

$15.58

Enterprise value

$119.16B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

The equity has grown by 29% YoY and by 5% from the previous quarter

The EPS has increased by 23% year-on-year and by 11% since the previous quarter

Vertex Pharmaceuticals's quick ratio has decreased by 20% YoY and by 13% QoQ

The price to earnings (P/E) is 20% more than the 5-year quarterly average of 27.1 and 20% more than the last 4 quarters average of 27.1

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

258.05M

Market cap

$127.6B

Enterprise value

$119.16B

Price to earnings (P/E)

31.74

Price to book (P/B)

6.89

Price to sales (P/S)

12.54

EV/EBIT

24.77

EV/EBITDA

23.8

EV/Sales

11.7

Revenue

$10.19B

EBIT

$4.81B

EBITDA

$5.01B

Free cash flow

$3.72B

Per share
Balance sheet
Liquidity

EPS

$15.58

Free cash flow per share

$14.4

Book value per share

$71.8

Revenue per share

$39.45

TBVPS

$85.18

Total assets

$23.92B

Total liabilities

$5.37B

Debt

$721.3M

Equity

$18.55B

Working capital

$9.49B

Debt to equity

0.04

Current ratio

3.5

Quick ratio

3.15

Net debt/EBITDA

-1.69

Margins
Efficiency
Dividend

EBITDA margin

49.2%

Gross margin

86.9%

Net margin

39.5%

Operating margin

40.7%

Return on assets

18.1%

Return on equity

23.6%

Return on invested capital

65.5%

Return on capital employed

23.9%

Return on sales

47.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

-2.24%

1 week

-0.16%

1 month

4.36%

1 year

37.96%

YTD

21.52%

QTD

5.49%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$10.19B

Gross profit

$8.85B

Operating income

$4.14B

Net income

$4.02B

Gross margin

86.9%

Net margin

39.5%

Vertex Pharmaceuticals's net income has increased by 23% YoY and by 11% QoQ

VRTX's net margin is up by 12% YoY and by 8% QoQ

VRTX's revenue is up by 11% YoY and by 3.2% QoQ

The operating income has grown by 10% since the previous quarter and by 3.7% year-on-year

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

31.74

P/B

6.89

P/S

12.54

EV/EBIT

24.77

EV/EBITDA

23.8

EV/Sales

11.7

The EPS has increased by 23% year-on-year and by 11% since the previous quarter

The price to earnings (P/E) is 20% more than the 5-year quarterly average of 27.1 and 20% more than the last 4 quarters average of 27.1

The equity has grown by 29% YoY and by 5% from the previous quarter

The stock's price to book (P/B) is 21% more than its last 4 quarters average of 5.8 and 5% more than its 5-year quarterly average of 6.7

The price to sales (P/S) is 29% more than the 5-year quarterly average of 9.9 and 28% more than the last 4 quarters average of 10.0

VRTX's revenue is up by 11% YoY and by 3.2% QoQ

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital has declined by 32% year-on-year and by 6% since the previous quarter

VRTX's return on assets is up by 4.6% since the previous quarter but it is down by 3.7% year-on-year

The return on sales has increased by 5% since the previous quarter and by 3.1% year-on-year

The return on equity has grown by 4.4% since the previous quarter but it has declined by 3.7% year-on-year

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's total assets has increased by 26% YoY and by 5% QoQ

Vertex Pharmaceuticals's quick ratio has decreased by 20% YoY and by 13% QoQ

VRTX's debt is 96% lower than its equity

The equity has grown by 29% YoY and by 5% from the previous quarter

The debt to equity fell by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.